Acacia Pharma Group plc Transparency Notification
05 March 2021 - 7:05PM
UK Regulatory
TIDMACPH
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
PUBLICATION RELATING TO A TRANSPARENCY NOTIFICATION
(ARTICLE 14, 1(ST) PARAGRAPH, OF THE LAW OF 2 MAY 2007 ON THE DISCLOSURE
OF MAJOR HOLDINGS)
-------------------------------------------------------------------------
Acacia Pharma Group plc
1. Summary of the notification
Cambridge, UK and Indianapolis, US -- 05 March 2021, 09:00 CET: Acacia
Pharma Group plc has received a transparency notification dated 02 March
2021 indicating that Coltrane Asset Management L.P. now holds, by virtue
of the purchase of shares on 18 February 2021, 5.50% of the voting
rights of the company. Coltrane has therefore crossed the threshold of
5%.
2. Content of notification
The notification dated 2 March 2021 contains the following information:
-- Reason of the notification -- acquisition or disposal of voting
securities or voting rights
-- Notification by -- a parent undertaking or a controlling person
-- Persons subject to the notification requirement:
Name Address (for legal entities)
----------------------------------- -----------------------------------
Mandeep Manku 250 W 55(th) St 16C
New York, NY 10019
----------------------------------- -----------------------------------
Coltrane Asset Management Holdings, 94 Solaris Avenue
Ltd Camana Bay, Grand Cayman KY1-1108,
Cayman Islands
----------------------------------- -----------------------------------
Coltrane Asset Management, L.P. 94 Solaris Avenue
Camana Bay, Grand Cayman KY1-1108,
Cayman Islands
----------------------------------- -----------------------------------
-- Date on which the threshold is crossed -- 18 February 2021
-- Threshold that is crossed -- 5%
-- Denominator -- 89,689,451
-- Notified details:
Previous
A) Voting rights notification After the transaction
------------------ ------------- -----------------------------------------------------------
# of voting
rights # of voting rights % of voting rights
------------------ ------------- ------------------------------ ---------------------------
Holders of voting Linked Not linked Linked to Not linked
rights to securities to securities securities to securities
------------------ ------------- -------------- -------------- ----------- --------------
Mandeep Manku 0 0 0.00% 0.00%
--------------------------------- -------------- -------------- ----------- --------------
Coltrane Asset
Management, L.P. 4,931,684 0 5.50% 0.00%
--------------------------------- -------------- -------------- ----------- --------------
Subtotal 4,931,684 5.50%
--------------------------------- -------------- -------------- ----------- --------------
TOTAL 4,931,684 0 5.50% 0.00%
-------------- -------------- ----------- --------------
B) Voting rights After the transaction
----------------------- -----------------------------------------------------------------------------------
# of voting
rights
that may
be acquired
Exercise if the
Holders of equivalent Type of financial Expiration period instrument % of voting
financial instruments instrument date or date is exercised rights Settlement
----------------------- ------------------ ----------- ---------- ------------- ----------- ----------
TOTAL 0 0.00%
------------- -----------
# of voting % of voting
TOTAL (A+B) rights rights
---------- ------------- -----------
CALCULATE 4,931,684 5.50%
----------------------------------------------------------------- ------------- -----------
Full chain of controlled undertakings through which the holding is
effectively held:
-- Coltrane Asset Management, L.P. is an investment advisor which manages
funds and accounts which hold the shares reported in this filing.
-- Coltrane Asset Management, L.P. can exercise the voting rights at its
discretion, without any instruction from its clients.
-- Coltrane Asset Management, L.P. is controlled by Coltrane Asset
Management Holdings, Ltd, which is controlled by Mandeep Manku.
1. Miscellaneous
-- This press release is available on Acacia Pharma Group plc's
website (
https://acaciapharma.com/investors/regulatory-announcements
https://acaciapharma.com/investors/regulatory-announcements)
-- The notification may be found on Acacia Pharma Group plc's website
(( https://acaciapharma.com/investors/regulatory-announcements
https://acaciapharma.com/investors/regulatory-announcements)
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
---------------------------------- --------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
---------------------------------- --------------------------------------
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
marketed in the US for the management of postoperative nausea & vomiting
(PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centered in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
www.acaciapharma.com
Attachment
-- TR-1BE_ACPH BB_03.02.21_ACPH_Signed
https://ml-eu.globenewswire.com/Resource/Download/79e06a89-c7ba-4b2a-bc11-1e4f0d40eab4
(END) Dow Jones Newswires
March 05, 2021 03:05 ET (08:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024
